

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

NATURES SUNSHINE PRODUCTS INC

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

639027101

(CUSIP Number)

Yuqing Chen
Shanghai Fosun Pharmaceutical (Group) Co, Ltd., No.1289 Yishan Road
Shanghai, F4, 200233
86 (21) 33987000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/05/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 639027101

1	Name of reporting person Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) WC

5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization CHINA	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 2,918,774.00
	8	Shared Voting Power
	9	Sole Dispositive Power 2,918,774.00
	10	Shared Dispositive Power
11	Aggregate amount beneficially owned by each reporting person 2,918,774.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 15.9 %	
14	Type of Reporting Person (See Instructions) CO	

SCHEDULE 13D

CUSIP No.	639027101
-----------	-----------

1	Name of reporting person Fosun Pharma USA Inc.
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 2,854,607.00
	8	Shared Voting Power
	9	Sole Dispositive Power 2,854,607.00
	10	Shared Dispositive Power
11	Aggregate amount beneficially owned by each reporting person 2,854,607.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 15.6 %	
14	Type of Reporting Person (See Instructions) CO	

SCHEDULE 13D

Item 1. Security and Issuer

- (a) **Title of Class of Securities:**
Common Stock, no par value
- (b) **Name of Issuer:**
NATURES SUNSHINE PRODUCTS INC
- (c) **Address of Issuer's Principal Executive Offices:**
2901 West Bluegrass Blvd., Suite 100, Lehi, UTAH , 84043.

Item 1 Comment:

This Amendment No. 2 to Schedule 13D amends the statement on Schedule 13D originally filed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") with the Securities and Exchange Commission ("SEC") on August 4, 2014, as amended by Amendment No. 1 filed with the SEC on September 2, 2014 (the "Original Schedule 13D," and together with Amendment No. 1, and this Amendment No. 2, the "Schedule 13D") relating to the common stock, no par value (the "Common Stock"), of Nature's Sunshine Products, Inc., a Utah corporation (the "Issuer"). In addition to other matters described herein, this Amendment No. 2 is being filed to report the transfer of 2,854,607 shares of Common Stock from Fosun Pharma to Fosun Pharma USA Inc. ("FPUSA"), a Delaware corporation and wholly-owned subsidiary of Fosun Pharma, and the inclusion of FPUSA as an additional Reporting Person as a result thereof. Fosun Pharma and FPUSA are referred to herein collectively as the "Reporting Persons."

Item 2. Identity and Background

- (a) Item 2 of the Scheduled 13D is amended by adding the following information:
(a)-(c), (f):
FPUSA is a Delaware corporation. Its principal place of business is 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540. FPUSA is a specialty pharmaceutical company.
Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
FPUSA is a wholly-owned subsidiary of Fosun Pharma.
Exhibit 99.1 (filed herewith) amends and restates the Exhibit 99.1 filed with the Original Schedule 13D and is incorporated herein by reference.
- (d) During the past five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

- (e) During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is amended by adding the following information:

On June 5, 2025, Fosun Pharma contributed 2,854,607 shares of Common Stock to FPUSA. The Reporting Persons may dispose or continue to hold all or a portion of the shares of Common Stock reported herein, subject to the Reporting Persons' evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors.

Item 5. Interest in Securities of the Issuer

- (a) The information from Items 7-11, inclusive, and Item 13 on the cover pages of this Schedule 13D is incorporated herein by reference. The beneficial ownership percentages used in this Schedule 13D are calculated based on a total of 18,350,801 shares of Common Stock outstanding as of April 18, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025.
- (b) The Reporting Persons have sole voting and dispositive power over an aggregate of 2,918,774 shares of Common Stock. FPUSA directly owns 2,854,607 shares of Common Stock, and Fosun Industrial Co., Limited ("Fosun Industrial") directly owns 64,167 shares of Common Stock. Fosun Pharma, as the parent of FPUSA and Fosun Industrial, indirectly beneficially owns the 2,918,774 shares of Common Stock directly owned by FPUSA and Fosun Industrial.
- (c) Except as described in Item 4 of this Schedule 13D, there have been no transactions in shares of Common Stock or any other securities of the Issuer by the Reporting Persons in the 60 days prior to the filing of this Amendment No. 2.
- (d) Except as set forth in this Schedule 13D, to the knowledge of the Reporting Persons, no person had the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities covered by this Schedule 13D.
- (e) Not applicable.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Amended list of directors and executive officers of Fosun Pharma, persons controlling Fosun Pharma and executive officers and directors of other persons in control of Fosun Pharma (filed herewith).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Shanghai Fosun Pharmaceutical (Group) Co.,
Ltd.

Signature: /s/ Yuqing Chen
Name/Title: Yuqing Chen / Chairman
Date: 06/09/2025

Fosun Pharma USA Inc.

Signature: /s/ Yuqing Wang
Name/Title: Yuqing Wang / Chief Financial Officer
Date: 06/09/2025

**DIRECTORS AND EXECUTIVE OFFICERS OF FOSUN PHARMA PERSONS CONTROLLING FOSUN PHARMA AND EXECUTIVE OFFICERS AND
DIRECTORS OF OTHER PERSONS IN CONTROL OF FOSUN
PHARMA, FPUSA AND FOSUN INDUSTRIAL**

Fosun Pharma is a corporation organized under the laws of the People's Republic of China and listed on both the Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited with its principal business address at Building A, No. 1289 Yishan Road Shanghai, 200233, China. Fosun Pharma is an innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Pharma is set forth below.

Fosun Pharma

Name	Business address	Present Principal Employment	Citizenship
Chen Yuqing	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Executive Director, Chairman of the Board of Directors	China
Guan Xiaohui	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Executive Director, Co-Chairman of the Board of Directors	China
Wen Deyong	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Executive Director, Deputy Chairman of the Board of Directors, Chief Executive Officer	China
Wang Kexin	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Executive Director	China
Chen Qiyu	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Non-executive Director	China
Xu Xiaoliang	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Non-executive Director	China
Pan Donghui	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Non-executive Director	Hong Kong, China
Wu Yifang	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Non-executive Director	China
Li Ling	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Independent Non-executive Director	China
Tang Guliang	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Independent Non-executive Director	China
Wang Quandi	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Independent Non-executive Director	China
Yu Tze Shan Hailson	Building A, No. 1289 Yishan Road Shanghai, 200233, China	Independent Non-executive Director	Hong Kong, China

Fosun Pharma is a subsidiary of Fosun High Technology. Fosun High Technology is a corporation organized under the laws of the People's Republic of China with its principal business address at 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China. Fosun High Technology is a subsidiary of Fosun International, which is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun High Technology is set forth below.

Fosun High Technology			
Name	Business Address	Present Principal Employment	Citizenship
Chen Qiyu	16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China	Chairman of the Board of Directors	China
Xu Xiaoliang	16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China	Director and general manager	China
Gong Ping	16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China	Director	China

Fosun High Technology is a subsidiary of Fosun International. Fosun International is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International's ordinary shares are listed on the main board of The Stock Exchange of Hong Kong Limited. Fosun International is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International is set forth below.

Fosun International			
Name	Business Address	Present Principal Employment	Citizenship
GUO Guangchang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Chairman	Hong Kong, China
WANG Qunbin	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-Chairman	Hong Kong, China
CHEN Qiyu	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-Chief Executive Officer	China
XU Xiaoliang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-Chief Executive Officer	China
GONG Ping	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director, Executive President and Chief Financial Officer	China
HUANG Zhen	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Executive President	China
PAN Donghui	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director, Executive President and Chief Human Resources Officer	Hong Kong, China
LI Shupe	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Non-executive Director	China
LI Fuhua	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Non-executive Director	China
ZHANG Shengman	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Independent Non-executive Director	Hong Kong, China
ZHANG Huaqiao	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Independent Non-executive Director	Hong Kong, China
David T. ZHANG	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Independent Non-executive Director	Hong Kong, China
LEE Kai-Fu	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Independent Non-executive Director	Republic of China
TSANG King Suen Katherine	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Independent Non-executive Director	Hong Kong, China

Fosun International is a subsidiary of Fosun Holdings. Fosun Holdings is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Holdings is set forth below.

Fosun Holdings			
Name	Business Address	Present Principal Employment	Citizenship
GUO Guangchang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China
LAW Tsz Kwan Iris	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China
LI Tao	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China

Fosun Holdings is a subsidiary of Fosun International Holdings. Fosun International Holdings is a corporation organized under the laws of British Virgin Islands with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International Holdings is set forth below.

Fosun International Holdings			
Name	Business Address	Present Principal Employment	Citizenship
GUO Guangchang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China
LAW Tsz Kwan Iris	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China
LI Tao	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director	Hong Kong, China

Fosun International Holdings is owned 82.59% by Guangchang Guo with the remaining shares owned 17.41% by Qunbin Wang. Guangchang Guo’s principal business address is Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. He is a citizen of Hong Kong, China.

The name, business address, present principal employment and citizenship of each director and executive officer of FPUSA is set forth below.

Fosun Pharma USA Inc.			
Name	Business address	Present Principal Employment	Citizenship
Wu Yifang	104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540	Director	China
Zhang Wenjie	104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540	Director	US Citizen
Feng Rongli	104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540	Director	China

FPUSA is a wholly owned subsidiary of Fosun Pharma. FPUSA is a Delaware corporation. Its principal place of business is 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540. FPUSA is a specialty pharmaceutical company.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Industrial is set forth below.

Fosun Industrial			
Name	Business address	Present Principal Employment	Citizenship
Guan Xiaohui	Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	Chairman of the Board of Director	China
LAW Tsz Kwan Iris	Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	Director	Hong Kong, China
HUNG HSIU YING SAMMI	Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	Director	Hong Kong, China

Fosun Industrial is a wholly owned subsidiary of Fosun Pharma. The address of the principal business office for Fosun Industrial is Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. Fosun Industrial is a company incorporated under the laws of Hong Kong. Fosun Industrial is principally engaged in foreign investment, sale and consultancy service of Chinese and western medicine, diagnostic reagent, medical device products and relevant import and export business.
